 |
|
|
| |
THE IMPACT OF BROADER HEPATITIS C VIRUS TREATMENT STRATEGIES ON POPULATION HEALTH AND SOCIAL VALUE IN ENGLAND
|
| |
| |
Reported by Jules Levin
EASL 2017 April 19-23 Amsterdam Netherlands
Karen Van Nuys, PhD1 ⋅ Jacquelyn W. Chou, MPP, MPL1 ⋅ Alison R. Silverstein, MPH1 ⋅ Ronald Brookmeyer, PhD2 ⋅ Dana Goldman, PhD3
1Precision Health Economics, Los Angeles, CA, USA. 2. University of California, Los Angeles, CA, USA. 3. University of Southern California, Los Angeles, CA, USA.
Limiting HCV treatment to those with severe liver damage has no impact on reducing the incident population of HCV over time. This approach lowers treatment costs but generates fewer health benefits, higher medical expenditures, and lower productivity. In the long term, broader HCV treatment in England would lead to £7.8 billion in greater social value from more QALYs, lower medical expenditures, and increased productivity, likely due to treating active disease transmitters at an earlier disease stage, reducing the incident population over time. Strategies that tie reimbursement to long-term benefits while providing expanded access should be explored, as they have the potential to create significant value.
|
| |
|
|
|
|
|
